Radiopharmaceutical Therapy Use Rose 2,000% in a Decade. New Data Define Its Benefits and
A meta-analysis of 7 trials with 2,500+ patients found Lu-177 PSMA-617 consistently improved progression-free survival in metastatic castration-resistant prostate cancer without significantly increasing severe side effects. Separately, Medicare data show radiopharmaceutical therapy administrations g